Alloplex Biotherapeutics

Founded in 2016, Alloplex Biotherapeutics is developing a patented immune cell retraining platform (ENLIST) that activates multiple immune pathways simultaneously to create potent, non-genetically engineered therapeutic cells. Its lead program, SUPLEXA, achieved all endpoints in a Phase 1 trial in 35 heavily pre-treated solid tumor patients, showing a pristine safety profile and clinical activity, including complete and partial responses. The company is positioned at the forefront of next-generation cellular therapy, with a scalable manufacturing process and a platform capable of augmenting CAR-T and allogeneic approaches.

The ENLIST platform is a patented immune cell training system that uses engineered cell lines expressing multiple immunomodulatory ligands to 'retrain' a patient's own immune cells ex vivo, activating synergistic pathways without genetic engineering.

Alloplex competes with engineered cell therapy leaders (e.g., Kite, Novartis) and solid tumor cell therapy pioneers (e.g., Iovance). Its main differentiation is a pristine safety profile from its non-engineered approach, a multimodal mechanism of action, and a simple, scalable manufacturing process compared to complex CAR-T production.